# An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

> **NCT01787279** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 59 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT01787279
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01787279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01787279, "An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01787279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*